CG
RNXT icon

Colony Group’s RenovoRx RNXT Stock Holding History

Colony Group’s Portfolio RNXT Stock Details RNXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,741
Closed -$37K – 851
2022
Q4 		$37K Hold
15,741
– – ﹤0.01% 820
2022
Q3 		$32K Buy
+15,741
New +$34.2K ﹤0.01% 768
2022
Q2 		– Sell
-15,508
Closed -$45K – 859
2022
Q1 		$45K Buy
+15,508
New +$54.3K ﹤0.01% 831

Other funds holding RNXT

Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
ACA
Affinity Capital Advisors Berkeley, California $810M AUM 24.85% 1-Year Est. Return
LFAS
Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Colony Group's RNXT Position: Q1 2023 in Review

Colony Group sold out of RenovoRx (RNXT) in Q1 2023, closing a stake of 15,741 shares — an estimated $37K sold.

Colony Group first reported a position in RNXT in Q1 2022 and held it in 3 quarters. The position peaked at $45K in Q1 2022. 12 funds tracked by Wall St. Rank hold RNXT as of Q1 2023.

  • Colony Group reported no remaining RenovoRx position as of Q1 2023 after selling out during the quarter.
  • Colony Group sold 15,741 RenovoRx shares in Q1 2023, an estimated $37K.
  • Colony Group first reported a position in RenovoRx in Q1 2022 and held it in 3 quarters.
  • Colony Group's RenovoRx position peaked at $45K in Q1 2022.
  • 12 funds tracked by Wall St. Rank held RenovoRx as of Q1 2023.

Based on Colony Group's 13F filing for Q1 2023, filed 16 May 2023.